QFA
AKRO

Quattro Financial Advisors’s Akero Therapeutics AKRO Stock Holding History

Quattro Financial Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$251K – 85
2024
Q4 		$251K Hold
10,000
– – 0.06% 75
2024
Q3 		$295K Sell
10,000
-10,000
-50% -$261K 0.08% 66
2024
Q2 		$469K Buy
20,000
+10,000
+100% +$214K 0.12% 57
2024
Q1 		$253K Buy
10,000
+9,977
+43,378% +$240K 0.07% 69
2023
Q4 		$234K Buy
+23
New +$454 0.08% 77

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Quattro Financial Advisors's AKRO Position: Q1 2025 in Review

Quattro Financial Advisors sold out of Akero Therapeutics (AKRO) in Q1 2025, closing a stake of 10,000 shares — an estimated $251K sold.

Quattro Financial Advisors first reported a position in AKRO in Q4 2023 and held it in 5 quarters. The position peaked at $469K in Q2 2024. 240 funds tracked by Wall St. Rank hold AKRO as of Q1 2025.

  • Quattro Financial Advisors reported no remaining Akero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Quattro Financial Advisors sold 10,000 Akero Therapeutics shares in Q1 2025, an estimated $251K.
  • Quattro Financial Advisors first reported a position in Akero Therapeutics in Q4 2023 and held it in 5 quarters.
  • Quattro Financial Advisors's Akero Therapeutics position peaked at $469K in Q2 2024.
  • 240 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2025.

Based on Quattro Financial Advisors's 13F filing for Q1 2025, filed 29 Apr 2025.